PHARMACYTE BIOTECH INC (PMCB)

US71715X2036 - Common Stock

2.12  -0.08 (-3.64%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PMCB. PMCB was compared to 588 industry peers in the Biotechnology industry. While PMCB has a great health rating, there are worries on its profitability. PMCB does not seem to be growing, but still is valued expensively.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PMCB has reported negative net income.
In the past year PMCB has reported a negative cash flow from operations.
PMCB had negative earnings in each of the past 5 years.
In the past 5 years PMCB always reported negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of -16.13%, PMCB belongs to the best of the industry, outperforming 86.47% of the companies in the same industry.
With an excellent Return On Equity value of -23.54%, PMCB belongs to the best of the industry, outperforming 85.10% of the companies in the same industry.
Industry RankSector Rank
ROA -16.13%
ROE -23.54%
ROIC N/A
ROA(3y)-19.52%
ROA(5y)-38.21%
ROE(3y)-21.27%
ROE(5y)-43.96%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PMCB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

PMCB has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PMCB has been increased compared to 5 years ago.
PMCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -1.18, we must say that PMCB is in the distress zone and has some risk of bankruptcy.
PMCB has a Altman-Z score of -1.18. This is comparable to the rest of the industry: PMCB outperforms 54.62% of its industry peers.
There is no outstanding debt for PMCB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.18
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 8.16 indicates that PMCB has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.16, PMCB is doing good in the industry, outperforming 73.97% of the companies in the same industry.
PMCB has a Quick Ratio of 8.16. This indicates that PMCB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PMCB (8.16) is better than 74.14% of its industry peers.
Industry RankSector Rank
Current Ratio 8.16
Quick Ratio 8.16

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PMCB have decreased strongly by -389.11% in the last year.
EPS 1Y (TTM)-389.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1532.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PMCB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMCB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACYTE BIOTECH INC

NASDAQ:PMCB (4/25/2024, 11:22:01 AM)

2.12

-0.08 (-3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.91M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.13%
ROE -23.54%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8.16
Quick Ratio 8.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-389.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y